Leerink Partnrs Issues Positive Outlook for Moderna Earnings

Moderna, Inc. (NASDAQ:MRNA) – Investment analysts at Leerink Partnrs boosted their FY2026 EPS estimates for Moderna in a report issued on Wednesday, October 22nd. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($7.60) per share for the year, up from their prior forecast of ($7.73). The consensus estimate for Moderna’s current full-year earnings is ($9.61) per share. Leerink Partnrs also issued estimates for Moderna’s FY2027 earnings at ($4.88) EPS and FY2028 earnings at ($3.33) EPS.

Several other equities analysts have also issued reports on the company. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Monday, October 20th. Morgan Stanley raised their price objective on Moderna from $31.00 to $32.00 and gave the company an “equal weight” rating in a research note on Friday, October 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Moderna in a research note on Wednesday, October 8th. Barclays dropped their target price on shares of Moderna from $40.00 to $31.00 and set an “equal weight” rating for the company in a report on Monday, August 4th. Finally, Cowen began coverage on shares of Moderna in a research note on Sunday, July 13th. They issued a “hold” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, twelve have given a Hold rating and five have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $36.86.

Moderna Price Performance

Shares of MRNA opened at $26.66 on Monday. The firm has a 50 day simple moving average of $25.91 and a two-hundred day simple moving average of $27.15. Moderna has a one year low of $23.15 and a one year high of $57.69. The company has a market cap of $10.41 billion, a P/E ratio of -3.54 and a beta of 2.01.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating the consensus estimate of ($2.99) by $0.86. The company had revenue of $142.00 million during the quarter, compared to analysts’ expectations of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The business’s revenue for the quarter was down 41.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($3.33) EPS. Moderna has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC grew its holdings in Moderna by 149.8% during the 1st quarter. GAMMA Investing LLC now owns 7,926 shares of the company’s stock worth $225,000 after acquiring an additional 4,753 shares during the last quarter. Janney Montgomery Scott LLC lifted its holdings in shares of Moderna by 37.1% during the first quarter. Janney Montgomery Scott LLC now owns 13,825 shares of the company’s stock worth $392,000 after purchasing an additional 3,744 shares during the period. Asset Management One Co. Ltd. lifted its holdings in shares of Moderna by 5.9% during the first quarter. Asset Management One Co. Ltd. now owns 130,325 shares of the company’s stock worth $3,695,000 after purchasing an additional 7,274 shares during the period. Bessemer Group Inc. grew its stake in shares of Moderna by 133.9% in the first quarter. Bessemer Group Inc. now owns 11,604 shares of the company’s stock worth $329,000 after purchasing an additional 6,642 shares during the last quarter. Finally, Diversified Trust Co bought a new stake in Moderna in the first quarter valued at $387,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.